Biden-Harris Administration Proposes Medicare $2 Drug List Model To Lower Prescription Costs; CMS Seeks Feedback On Sample Drug List And Outreach With Voluntary Participation For Part D Sponsors Starting As Early As Jan 2027; Model To Include Drugs For Common Conditions With Periodic Updates Based On New Generics, Clinical Indications, And Pricing Trends
Portfolio Pulse from Benzinga Newsdesk
The Biden-Harris Administration has proposed a Medicare $2 Drug List Model aimed at reducing prescription costs. The Centers for Medicare & Medicaid Services (CMS) is seeking feedback on a sample drug list and plans to start voluntary participation for Part D sponsors as early as January 2027. The model will include drugs for common conditions and will be updated periodically based on new generics, clinical indications, and pricing trends.
October 09, 2024 | 12:57 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cigna (CI) may be impacted by the proposed Medicare $2 Drug List Model as it could affect pricing and participation in Medicare Part D plans.
Cigna, as a provider of Medicare Part D plans, may need to adjust its pricing and participation strategies based on the new model, but the impact is uncertain until more details are available.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Centene (CNC) could be affected by the Medicare $2 Drug List Model, influencing its Medicare Part D offerings and pricing strategies.
As a major player in Medicare Part D, Centene may need to adapt its offerings and pricing, but the exact impact will depend on the final details of the model.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
CVS Health (CVS) may experience changes in its Medicare Part D business due to the proposed $2 Drug List Model.
CVS Health, involved in Medicare Part D, might need to adjust its business model and pricing strategies, but the specific effects are unclear until more information is available.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Humana (HUM) could be impacted by the Medicare $2 Drug List Model, affecting its Medicare Part D plans and pricing.
As a significant provider of Medicare Part D plans, Humana may have to adjust its offerings and pricing strategies, but the impact is uncertain until more details are released.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
UnitedHealth Group (UNH) may be affected by the proposed Medicare $2 Drug List Model, influencing its Medicare Part D offerings.
UnitedHealth Group, as a provider of Medicare Part D plans, may need to adjust its business model and pricing strategies, but the specific effects are unclear until more information is available.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50